(주)셀렉스라이프사이언스

News

ILIAS is the Leader of Next-Generation Exosome Therapeutics.

[ENG] 보도자료

ILIAS Biologics begins KOSDAQ listing process

페이지 정보

  • 작성자 : ILIAS Biologics
  • 작성일 : 20-11-04 11:39
  • 조회 : 51회

본문

 

28 Oct 2020

 

ILIAS Biologics begins KOSDAQ listing process

 

ILIAS Biologics has been recently finalizing the underwriter contract with two securities companies, Kiwoom Securities and Daishin Securities, preparing for an initial public offering (IPO) on the KOSDAQ (Korea Securities Dealers and Automated Quotation) in Q1 2022.

We are grateful for the trust they have shown us from investing in Series B to participating as an underwriter. 

 

Please find the link below for more information.

 

(Kor)

개인정보취급방침

닫기

이메일주소무단수집거부

닫기

사이트맵

사이트맵

몬트리올의정서
국내이행법령
사업안내
특정물질 수출입
알림·자료실
민원서비스
닫기